Zidesamtinib (NVL-520)

Zidesamtinib · Nuvalent Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Zidesamtinib (NVL-520), covering 2025-10-24 to 2025-10-24. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) [Phase 1, Phase 2]

See pricing